Bdparp — Olaparib
Olaparib was among the first PARP inhibitors to reach the oncology market and remains a genetically precise treatment option — it works specifically in tumors with BRCA mutations or broader homologous recombination deficiency, meaning like Cetuximab and Crizotinib in our catalogue, biomarker testing at the receiving facility directly determines whether the drug will actually benefit a given patient, not just whether it's clinically appropriate.
- Approved indications: BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, in various treatment-line settings depending on specific approval
- Mechanism: Inhibits PARP enzymes involved in DNA repair — in cancer cells that already have defective DNA-repair machinery due to BRCA mutations, this additional inhibition causes cell death through accumulated DNA damage the cell cannot fix
- Prescribing prerequisite: Confirmed BRCA mutation or HRD (homologous recombination deficiency) status via genetic testing is required before starting in most indications
- Regional relevance: Growing export demand as genetic testing infrastructure expands across LATAM and parts of Asia, widening the population of patients eligible for this precision therapy
Why Source Bdparp Through Us?
-
Established oncology API: Olaparib is a targeted oral PARP inhibitor used in specific cancer treatment settings where the relevant clinical and biomarker criteria are met.
-
Defined 150 mg presentation: The product provides Olaparib in a 150 mg tablet strength for oral administration.
-
India-based pharmaceutical sourcing: The Indian Pharma provides a structured channel for sourcing Olaparib from India for eligible international and institutional requirements.
-
Requirement-based procurement: Availability and commercial terms can be assessed according to strength, pack, quantity, destination and applicable pharmaceutical requirements.
Key Product Facts
150 mg
Strength
28 Tablet (S) In A Bottle
Pack Size
Olaparib
Active Ingredient
Oncology
Category
Enquire Now for Pricing
Price
Olaparib was among the first PARP inhibitors to reach the oncology market and remains a genetically precise treatment option — it works specifically in tumors with BRCA mutations or broader homologous recombination deficiency, meaning like Cetuximab and Crizotinib in our catalogue, biomarker testing at the receiving facility directly determines whether the drug will actually benefit a given patient, not just whether it's clinically appropriate.
- Approved indications: BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, in various treatment-line settings depending on specific approval
- Mechanism: Inhibits PARP enzymes involved in DNA repair — in cancer cells that already have defective DNA-repair machinery due to BRCA mutations, this additional inhibition causes cell death through accumulated DNA damage the cell cannot fix
- Prescribing prerequisite: Confirmed BRCA mutation or HRD (homologous recombination deficiency) status via genetic testing is required before starting in most indications
- Regional relevance: Growing export demand as genetic testing infrastructure expands across LATAM and parts of Asia, widening the population of patients eligible for this precision therapy
- Myelosuppression: Regular blood count monitoring required throughout treatment
- Rare but serious risk: Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) has been reported with long-term use — periodic blood monitoring should continue even after extended treatment periods
- Pneumonitis: A rare but serious risk requiring prompt evaluation if respiratory symptoms develop
- Pregnancy: Contraindicated — significant teratogenicity risk, with effective contraception required during treatment and for a defined period after the last dose
Documentation & Availability:
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics, no cold chain required
- Coverage: Global export markets, with growing relevance in markets expanding genetic-testing access
- Tracking: Full shipment tracking included
What is Olaparib used for?
Treats BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.
Get Olaparib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Does it work for all cancer patients?
No, only patients with confirmed BRCA mutations or homologous recombination deficiency respond — genetic testing is required before treatment.
Are there long-term risks?
Rare but serious risks include blood disorders like MDS/AML with long-term use, requiring ongoing blood monitoring.
Who supplies Olaparib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
